These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24085610)

  • 1. Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia.
    Malchow B; Hasan A; Schneider-Axmann T; Jatzko A; Gruber O; Schmitt A; Falkai P; Wobrock T
    Eur Arch Psychiatry Clin Neurosci; 2013 Nov; 263 Suppl 2():S155-68. PubMed ID: 24085610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia.
    Ebdrup BH; Glenthøj B; Rasmussen H; Aggernaes B; Langkilde AR; Paulson OB; Lublin H; Skimminge A; Baaré W
    J Psychiatry Neurosci; 2010 Mar; 35(2):95-104. PubMed ID: 20184807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders.
    Koenders L; Machielsen MW; van der Meer FJ; van Gasselt AC; Meijer CJ; van den Brink W; Koeter MW; Caan MW; Cousijn J; den Braber A; van 't Ent D; Rive MM; Schene AH; van de Giessen E; Huyser C; de Kwaasteniet BP; Veltman DJ; de Haan L
    J Psychiatry Neurosci; 2015 May; 40(3):197-206. PubMed ID: 25510948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment.
    Emsley R; Asmal L; du Plessis S; Chiliza B; Kidd M; Carr J; Vink M
    Schizophr Res; 2015 Dec; 169(1-3):89-94. PubMed ID: 26441006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence.
    Malchow B; Hasan A; Fusar-Poli P; Schmitt A; Falkai P; Wobrock T
    Eur Arch Psychiatry Clin Neurosci; 2013 Feb; 263(1):3-13. PubMed ID: 22907121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developmentally stable whole-brain volume reductions and developmentally sensitive caudate and putamen volume alterations in those with attention-deficit/hyperactivity disorder and their unaffected siblings.
    Greven CU; Bralten J; Mennes M; O'Dwyer L; van Hulzen KJ; Rommelse N; Schweren LJ; Hoekstra PJ; Hartman CA; Heslenfeld D; Oosterlaan J; Faraone SV; Franke B; Zwiers MP; Arias-Vasquez A; Buitelaar JK
    JAMA Psychiatry; 2015 May; 72(5):490-9. PubMed ID: 25785435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla.
    Théberge J; Al-Semaan Y; Drost DJ; Malla AK; Neufeld RW; Bartha R; Manchanda R; Menon R; Densmore M; Schaefer B; Williamson PC
    Psychiatry Res; 2004 Jul; 131(2):107-14. PubMed ID: 15313517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals.
    Velakoulis D; Wood SJ; Wong MT; McGorry PD; Yung A; Phillips L; Smith D; Brewer W; Proffitt T; Desmond P; Pantelis C
    Arch Gen Psychiatry; 2006 Feb; 63(2):139-49. PubMed ID: 16461856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study.
    Tamagaki C; Sedvall GC; Jönsson EG; Okugawa G; Hall H; Pauli S; Agartz I
    Am J Psychiatry; 2005 Dec; 162(12):2315-21. PubMed ID: 16330596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia.
    Welch KA; Stanfield AC; McIntosh AM; Whalley HC; Job DE; Moorhead TW; Owens DG; Lawrie SM; Johnstone EC
    Br J Psychiatry; 2011 Nov; 199(5):386-90. PubMed ID: 21903664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
    Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
    Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy.
    Tandon N; Bolo NR; Sanghavi K; Mathew IT; Francis AN; Stanley JA; Keshavan MS
    Schizophr Res; 2013 Aug; 148(1-3):59-66. PubMed ID: 23791389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotic drug treatment for 6 months restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: A magnetic resonance spectroscopy study.
    Gan JL; Cheng ZX; Duan HF; Yang JM; Zhu XQ; Gao CY
    Psychiatry Res; 2014 Jul; 223(1):23-7. PubMed ID: 24831926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment.
    Chua SE; Deng Y; Chen EY; Law CW; Chiu CP; Cheung C; Wong JC; Lienenkaëmper N; Cheung V; Suckling J; McAlonan GM
    Psychol Med; 2009 May; 39(5):793-800. PubMed ID: 18713487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippocampal subdivision and amygdalar volumes in patients in an at-risk mental state for schizophrenia.
    Witthaus H; Mendes U; Brüne M; Ozgürdal S; Bohner G; Gudlowski Y; Kalus P; Andreasen N; Heinz A; Klingebiel R; Juckel G
    J Psychiatry Neurosci; 2010 Jan; 35(1):33-40. PubMed ID: 20040244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal asymmetries in subcortical brain volume in schizophrenia.
    Okada N; Fukunaga M; Yamashita F; Koshiyama D; Yamamori H; Ohi K; Yasuda Y; Fujimoto M; Watanabe Y; Yahata N; Nemoto K; Hibar DP; van Erp TG; Fujino H; Isobe M; Isomura S; Natsubori T; Narita H; Hashimoto N; Miyata J; Koike S; Takahashi T; Yamasue H; Matsuo K; Onitsuka T; Iidaka T; Kawasaki Y; Yoshimura R; Watanabe Y; Suzuki M; Turner JA; Takeda M; Thompson PM; Ozaki N; Kasai K; Hashimoto R
    Mol Psychiatry; 2016 Oct; 21(10):1460-6. PubMed ID: 26782053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users.
    Batalla A; Soriano-Mas C; López-Solà M; Torrens M; Crippa JA; Bhattacharyya S; Blanco-Hinojo L; Fagundo AB; Harrison BJ; Nogué S; de la Torre R; Farré M; Pujol J; Martín-Santos R
    Addict Biol; 2014 Jul; 19(4):722-32. PubMed ID: 23311613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia.
    Okugawa G; Nobuhara K; Takase K; Saito Y; Yoshimura M; Kinoshita T
    Neuropsychobiology; 2007; 55(1):43-6. PubMed ID: 17556852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients.
    Rais M; Cahn W; Van Haren N; Schnack H; Caspers E; Hulshoff Pol H; Kahn R
    Am J Psychiatry; 2008 Apr; 165(4):490-6. PubMed ID: 18281413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use.
    Hartberg CB; Lange EH; Lagerberg TV; Haukvik UK; Andreassen OA; Melle I; Agartz I
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):37-47. PubMed ID: 29254657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.